Biotech company Biocad reached a monthly production volume of the Sputnik V vaccine of 2 million doses, and plans to produce 5-6 million doses per month in summer, TASS reports citing the company’s deputy CEO Alexei Torgov.
According to him, since the launch of vaccine production at the company’s sites in November 2020, Biocad has already released about 3 million doses of the vaccine.
” We have achieved this gradually. I think closer to the second half of the year, June-July, “- answered Trades to the question about the timing of reaching the monthly issue of 5-6 million doses. Over the six months of 2021, the company will produce approximately 4-6 million doses of vaccines, he said on the sidelines of the Innoprom international industrial exhibition.
Biokad deputy CEO noted that it is difficult to predict the exact volume of vaccine production due to the complex production technology.
“This is not a chemical drug where you can take the substance and make tablets out of it, here is biology and there is always a very large error size, so we proceed from conservative forecasts,” he said. According to Trade, the drug is produced in millennial reactors in large series.
In September 2020, company Biocad (St. Petersburg) signed an agreement with the Gamalei Research Center for Epidemiology and Microbiology on the industrial production of the Sputnik V vaccine.